Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of HERANTIS PHARMA OYJ
No Price
28.04.2026 14:44
Current Prices from HERANTIS PHARMA OYJ
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ HELSINKI LTD
HRTIS.HE
EUR
28.04.2026 14:44
1,75 EUR
0,06 EUR
+3,31 %
Share Float & Liquidity
Free Float65,70 %
Shares Float17,41 M
Shares Outstanding26,5 M
Company Profile for HERANTIS PHARMA OYJ Share
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
